No Data
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. participated in the tenth batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the public announcement of the proposed selection results of national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's product, injectable ceftazidime sodium, is proposed to be selected for this centralized procurement. The sales revenue of injectable ceftazidime sodium from Lionco Pharmaceutical's wholly-owned subsidiary in 2023 amounted to 0 million yuan, accounting for 0% of the company's revenue for the year 2023; sales for the first three quarters of 2024.
Revenues Not Telling The Story For Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) After Shares Rise 29%
Is Lionco Pharmaceutical GroupLtd (SHSE:603669) Using Debt Sensibly?
Company Report for the Third Quarter of 2024 (after correction)
Announcement on additional information to the 2024 Third Quarter Report
lionco pharmaceutical group (603669.SH) subsidiary cephalosporin sodium for injection passed the generic drug consistency evaluation.
Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "...
Some Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Shareholders Look For Exit As Shares Take 31% Pounding
No Data
